HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.

AuthorsS Mitchell Harman, Eliot A Brinton, Frederick Naftolin, George R Merriam, Marcelle I Cedars, Ruth G Freeman, Nanette Santoro
JournalAnnals of internal medicine (Ann Intern Med) Vol. 153 Issue 1 Pg. 60-1; author reply 61-2 (Jul 06 2010) ISSN: 1539-3704 [Electronic] United States
PMID20621909 (Publication Type: Comment, Letter)
Chemical References
  • Estrogens, Conjugated (USP)
  • Medroxyprogesterone Acetate
Topics
  • Cardiovascular Diseases (epidemiology)
  • Data Interpretation, Statistical
  • Estrogen Replacement Therapy (adverse effects)
  • Estrogens, Conjugated (USP) (adverse effects)
  • Female
  • Humans
  • Medroxyprogesterone Acetate (adverse effects)
  • Postmenopause (drug effects)
  • Randomized Controlled Trials as Topic (standards)
  • Risk Factors
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: